AstraZeneca: FDA priority review for Imfinzi – BFM Bourse

AstraZeneca: FDA priority review for Imfinzi – BFM Bourse

Receive the value of the day every morning for free

The data collected is essential for these treatments and is intended for the relevant departments of BFM Bourse and, where applicable, its service providers. It is kept for the duration of the treatment and/or for the duration of the specific treatments to which you have consented and/or for the legal retention periods.
DCPs may be processed by authorized personnel of BFM Bourse, its subcontractors, partners or service providers. If the data collected is transferred outside the EU and processing is carried out there, this will be done, in accordance with the Regulations, on the basis of an adequacy decision by the European Commission or “standard contractual clauses”.

BFM Bourse, the data controller, implements personal data processing to manage its relationships with its customers and prospects.

In application of the regulations relating to the protection of personal data, you have a right of access, rectification, deletion, limitation and portability which is exercised: here
See our data privacy policy: ici

Leave a Replay